Loading...
Loading...
Browse all stories on DeepNewz
VisitWhat will be the impact on Express Scripts' stock price by January 31, 2025, following the lawsuit against the FTC?
Increase by more than 10% • 25%
Decrease by more than 10% • 25%
Change by less than 10% • 25%
Remain the same • 25%
Stock market data from financial news websites or stock exchanges
Express Scripts Sues FTC Over July Drug Pricing Report in St. Louis
Sep 20, 2024, 04:02 PM
Cigna's Express Scripts has filed a lawsuit against the U.S. Federal Trade Commission (FTC) over a recent report that criticizes pharmacy benefit managers (PBMs) for allegedly inflating drug prices. The lawsuit, which calls the report defamatory, demands that the FTC retract the report and seeks to prevent FTC Chair Lina Khan from participating in any actions related to Express Scripts. The FTC's report, released in July, accuses PBMs of raising drug costs, a claim that Express Scripts contests as misleading and biased. The lawsuit was filed in a federal court in St. Louis.
View original story
Increase by more than 10% • 25%
Decrease by more than 10% • 25%
No significant change (within ±10%) • 25%
Other • 25%
Express Scripts wins • 25%
FTC wins • 25%
Settlement reached • 25%
Case dismissed • 25%
UnitedHealth Group stock rises • 25%
Cigna Group stock rises • 25%
CVS Health stock rises • 25%
All stocks fall • 25%
Stock price increases • 33%
Stock price decreases • 33%
Stock price remains stable • 33%
Yes • 50%
No • 50%
Express Scripts fined • 25%
Express Scripts settles out of court • 25%
Express Scripts found not guilty • 25%
Case dismissed or no action taken • 25%
Stock price increases by over 10% • 25%
Stock price changes between -10% and +10% • 25%
Stock price decreases by over 10% • 25%
No significant change • 25%
FTC wins all lawsuits • 25%
FTC wins some lawsuits • 25%
FTC loses all lawsuits • 25%
Settlements reached • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Increase by more than 10% • 25%
Increase by less than 10% • 25%
Decrease by less than 10% • 25%
Decrease by more than 10% • 25%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
Take no further action • 25%
Other action • 25%
Release a new report • 25%
Initiate new regulations • 25%